BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1759 related articles for article (PubMed ID: 29249359)

  • 1. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m
    Su R; Dong L; Li C; Nachtergaele S; Wunderlich M; Qing Y; Deng X; Wang Y; Weng X; Hu C; Yu M; Skibbe J; Dai Q; Zou D; Wu T; Yu K; Weng H; Huang H; Ferchen K; Qin X; Zhang B; Qi J; Sasaki AT; Plas DR; Bradner JE; Wei M; Marcucci G; Jiang X; Mulloy JC; Jin J; He C; Chen J
    Cell; 2018 Jan; 172(1-2):90-105.e23. PubMed ID: 29249359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m
    Qing Y; Dong L; Gao L; Li C; Li Y; Han L; Prince E; Tan B; Deng X; Wetzel C; Shen C; Gao M; Chen Z; Li W; Zhang B; Braas D; Ten Hoeve J; Sanchez GJ; Chen H; Chan LN; Chen CW; Ann D; Jiang L; Müschen M; Marcucci G; Plas DR; Li Z; Su R; Chen J
    Mol Cell; 2021 Mar; 81(5):922-939.e9. PubMed ID: 33434505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-2HG Targets FTO to Increase m
    Cancer Discov; 2018 Feb; 8(2):137. PubMed ID: 29269348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m
    Sun K; Du Y; Hou Y; Zhao M; Li J; Du Y; Zhang L; Chen C; Yang H; Yan F; Su R
    Theranostics; 2021; 11(12):5831-5846. PubMed ID: 33897884
    [No Abstract]   [Full Text] [Related]  

  • 5. FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
    Xiao L; Li X; Mu Z; Zhou J; Zhou P; Xie C; Jiang S
    Cancer Res; 2020 Sep; 80(18):3945-3958. PubMed ID: 32680921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
    Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
    Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
    Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
    Chen JY; Lai YS; Tsai HJ; Kuo CC; Yen BL; Yeh SP; Sun HS; Hung WC
    Sci Rep; 2016 Aug; 6():32428. PubMed ID: 27577048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
    Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer.
    Yang Z; Jiang X; Zhang Z; Zhao Z; Xing W; Liu Y; Jiang X; Zhao H
    Cancer Gene Ther; 2021 Feb; 28(1-2):141-155. PubMed ID: 32655129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
    Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis.
    Zhang Z; Gao Q; Wang S
    J Cell Mol Med; 2021 Mar; 25(5):2655-2665. PubMed ID: 33533172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m
    Wang X; Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Shi H; Wang F; Wang Y
    Autophagy; 2020 Jul; 16(7):1221-1235. PubMed ID: 31451060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
    Pianka ST; Li T; Prins TJ; Eldred BSC; Kevan BM; Liang H; Zapanta Rinonos S; Kornblum HI; Nathanson DA; Pellegrini M; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    Cancer Res Commun; 2024 Mar; 4(3):876-894. PubMed ID: 38445960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
    J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
    Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
    Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.
    Liu L; Hu K; Feng J; Wang H; Fu S; Wang B; Wang L; Xu Y; Yu X; Huang H
    BMC Cancer; 2021 Jan; 21(1):36. PubMed ID: 33413208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.